Eye­Bio tar­gets reg­is­tra­tional tri­al af­ter ear­ly suc­cess of Wnt ag­o­nist in reti­nal dis­eases

Eye­Bio’s tri-spe­cif­ic Wnt ag­o­nist an­ti­body im­proved vi­su­al and anatom­i­cal mea­sures in a Phase Ib/IIa tri­al as a monother­a­py and in com­bi­na­tion with Re­gen­eron’s Eylea, prompt­ing pre­lim­i­nary plans for a po­ten­tial reg­is­tra­tional study in reti­nal dis­eases.

The biotech’s lead can­di­date Re­storet is de­signed to elim­i­nate leak­age in vas­cu­lar eye dis­eases by ac­ti­vat­ing the Wnt path­way to re­store and main­tain the blood-reti­nal bar­ri­er. The Phase Ib/IIa AMARONE tri­al was stopped ear­ly due to Re­storet’s promis­ing ef­fi­ca­cy and safe­ty, CEO David Guy­er told End­points News in an in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER